TORL BioTherapeutics is developing monoclonal antibodies and antibody-drug conjugates targeting specific molecular signatures in cancer to improve treatment outcomes for patients with solid tumors and blood cancers. The company addresses the unmet medical need for effective therapies by leveraging a strategic partnership with UCLA's Slamon Research Lab to advance its clinical pipeline.
Funding
$358.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors and blood cancers lack effective therapies, creating an unmet medical need for treatments that can improve patient outcomes. Current cancer treatments may not be effective due to the lack of specificity, leading to off-target effects and limited efficacy.
Solution
TORL BioTherapeutics is developing antibody-based therapies, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), that target specific molecular signatures expressed in cancer cells. These therapies are designed to selectively target cancer cells, improving treatment outcomes while minimizing off-target effects. TORL Bio's pipeline programs are focused on large, addressable markets with serious unmet medical needs, utilizing companion diagnostics to ensure the right drug is delivered to the right patient. The company leverages a strategic partnership with the Slamon Research Lab at UCLA to identify novel cancer targets and advance its pipeline through global clinical development.
Target Audience
The primary target audience includes patients with solid tumors and blood cancers who have unmet medical needs, as well as the clinicians who treat them.
Features
- Pipeline of antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) targeting specific cancer markers.
- Programs target molecular or genetic signatures coupled with companion diagnostics.
- TORL-1-23: ADC targeting Claudin 6 (CLDN6).
- TORL-2-307-ADC: ADC targeting Claudin 18.2 (CLDN18.2).
- TORL3600-001: ADC targeting CDH17.
- TORL4-500-001: ADC targeting Delta like non-canonical Notch Ligand 1 (DLK1).